List of Excipients in Branded Drug PSEUDOEPHEDRINE HCL

Generic Drugs Containing PSEUDOEPHEDRINE HCL

Company	Ingredient	NDC	Excipient
Better Living Brands LLC	pseudoephedrine hcl	21130-158	CELLULOSE, MICROCRYSTALLINE
Better Living Brands LLC	pseudoephedrine hcl	21130-158	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
Better Living Brands LLC	pseudoephedrine hcl	21130-158	HYDROXYPROPYL CELLULOSE

What are the Most Frequently-Used Excipients in PSEUDOEPHEDRINE HCL?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
2	HYDROXYPROPYL CELLULOSE

Pseudoephedrine HCl Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Pseudoephedrine hydrochloride is a mature, high-volume oral decongestant with limited active-ingredient patent leverage. Commercial differentiation is more likely to come from excipient-enabled delivery, dosing convenience, pediatric and sugar-free formats, abuse-deterrent packaging, manufacturing efficiency, and compliant combination products.

The strongest opportunities are extended-release tablets, low-sugar or sugar-free liquids, swallowability-focused solid dosage forms, and formulations that reduce misuse or improve supply-chain control. In the United States, pseudoephedrine products also face precursor-control requirements that materially affect packaging, distribution, retail sales, and inventory management under the Combat Methamphetamine Epidemic Act of 2005 (U.S. Congress, 2005).

What is the formulation profile of pseudoephedrine HCl?

Pseudoephedrine HCl is a water-soluble salt administered primarily in immediate-release and extended-release oral products. Common adult strengths include 30 mg and 60 mg immediate-release tablets, 120 mg 12-hour extended-release tablets, and 240 mg 24-hour extended-release tablets. Actual strengths and dosage instructions vary by product and jurisdiction.

Attribute	Formulation implication
Active ingredient	Pseudoephedrine hydrochloride
Primary route	Oral
Common dosage forms	Tablets, extended-release tablets, capsules, oral solutions, combination liquids
Immediate-release objective	Rapid dissolution and predictable onset
Extended-release objective	Controlled release over approximately 12 or 24 hours
Key excipient issues	Moisture control, powder flow, compaction, dissolution control, taste, preservative compatibility
Regulatory status	OTC or prescription status varies by jurisdiction and product
U.S. precursor controls	Retail sales, identification, transaction records, daily and annual quantity limits
Biosimilar exposure	None; pseudoephedrine HCl is a small-molecule active ingredient

Pseudoephedrine HCl is generally compatible with conventional oral solid-dose manufacturing, but its high aqueous solubility creates a central formulation problem: extended release is difficult to achieve with simple hydrophilic matrices unless polymer concentration, tablet dimensions, coating, and agitation-sensitive dissolution behavior are carefully controlled.

What excipients are used in pseudoephedrine HCl immediate-release tablets?

Immediate-release products typically use excipients that support direct compression or wet granulation, rapid disintegration, mechanical strength, and acceptable tablet appearance.

Common excipient functions

Function	Typical excipient classes	Strategic purpose
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate, starch	Controls tablet weight and improves manufacturability
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, sodium starch glycolate, crospovidone	Promotes rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow and content uniformity
Lubricant	Magnesium stearate, stearic acid, sodium stearyl fumarate	Reduces ejection force and tooling adhesion
Film coating	Hypromellose, polyethylene glycol, pigments, titanium dioxide where permitted	Improves appearance, handling, identification, and swallowability
Taste control	Sweeteners, flavors, polymer coatings	Relevant for chewables, liquids, and orally disintegrating products

A practical immediate-release platform uses microcrystalline cellulose or a calcium phosphate diluent with a superdisintegrant, colloidal silicon dioxide, and a low-level lubricant. Excessive lubricant concentration or overmixing can slow wetting and dissolution. The formulation should therefore control lubrication time, particle-size distribution, and compression force as critical process variables.

Lactose-free, dye-free, and gluten-free positioning can support retail differentiation, but these claims require product-specific supplier qualification, process controls, and labeling review. Excipients should be selected from established compendial grades where possible to reduce regulatory and supply risk.

What excipients are used in pseudoephedrine HCl extended-release products?

Extended-release pseudoephedrine products present the most technically defensible formulation opportunity. Because the drug is highly water soluble, a low-permeability matrix or membrane system is generally needed to prevent rapid drug liberation.

Hydrophilic matrix systems

Hydrophilic matrix tablets commonly rely on high-viscosity hypromellose or related hydrophilic polymers. Upon hydration, the polymer forms a gel layer that slows water ingress and drug diffusion. The formulation must balance polymer loading against tablet size, dose, target duration, and dose-dumping resistance.

Potential supporting excipients include:

• Microcrystalline cellulose for compressibility and matrix structure.
• Lactose or mannitol for soluble filler functions.
• Colloidal silicon dioxide for flow.
• Polyethylene glycol or other coating aids for film application.
• Magnesium stearate or sodium stearyl fumarate for lubrication.

A hydrophilic matrix may be commercially attractive because it can use conventional high-speed tablet equipment. Its limitations include sensitivity to compression force, tablet geometry, agitation conditions, and food effects.

Hydrophobic matrix systems

Ethylcellulose, waxes, fatty alcohols, and other water-insoluble materials can reduce drug release through diffusion barriers. Hydrophobic matrices may provide greater release control for a highly soluble active ingredient, but they can increase formulation complexity and create more demanding dissolution specifications.

Membrane-coated systems

A tablet or multiparticulate core can be coated with ethylcellulose, cellulose acetate, acrylic polymers, or combinations of permeable and pore-forming materials. Coated multiparticulates may improve release uniformity and reduce the consequences of mechanical damage to a single tablet unit.

Membrane systems create opportunities for process and formulation patents covering:

• Coating composition.
• Polymer ratios.
• Pore-former concentration.
• Coating weight gain.
• Multiparticulate size distribution.
• Dose-dumping resistance.
• Release profiles under fed and fasted conditions.

Those claims are product-specific. The existence of an extended-release formulation does not establish enforceable patent protection.

What excipient strategy is best for pseudoephedrine HCl liquids?

Liquid products are commercially relevant for pediatric and geriatric users, although pseudoephedrine use in children is constrained by age, labeling, and jurisdiction-specific safety requirements. The principal formulation challenges are taste, microbial control, viscosity, chemical stability, and sugar content.

Conventional syrup systems

Sucrose-based syrups provide sweetness, viscosity, and consumer familiarity. They can reduce the need for high-intensity sweeteners but are less suitable for diabetic consumers and products marketed for reduced sugar intake.

Sugar-free liquids

Sugar-free platforms may use sorbitol, glycerin, propylene glycol, sucralose, saccharin, acesulfame potassium, or combinations of these materials. The formulation must control:

• Osmolality and gastrointestinal tolerability.
• Sweetener aftertaste.
• Viscosity and pourability.
• Preservative effectiveness.
• Container compatibility.
• Assay and degradation over shelf life.

Sodium benzoate or potassium sorbate may be used in suitable pH systems, subject to product-specific compatibility and regulatory review. Citric acid or citrate buffers can support pH control, but excessive acidity may affect taste and preservative performance.

Alcohol-free and dye-free formats

Alcohol-free, dye-free, and allergen-conscious products are practical retail differentiation opportunities. These features are relatively easy for competitors to copy unless supported by a broader delivery or packaging system. Their value is strongest when combined with a clear consumer segment, such as pediatric caregivers, sensitive users, or institutional buyers.

What formulation patents could protect pseudoephedrine HCl products?

Pseudoephedrine HCl itself is a mature small molecule. New patent value is more likely to arise from formulation and delivery claims than from composition-of-matter claims.

Potential patentable subject matter includes:

1. Extended-release matrix compositions.
2. Multiparticulate or coated-pellet systems.
3. Abuse-deterrent formulations.
4. Tamper-resistant packaging integrated with dose administration.
5. Combination products with chemically or physically compatible actives.
6. Taste-masked liquids, chewables, or orally disintegrating tablets.
7. Manufacturing methods that improve content uniformity or release control.
8. Specific dissolution profiles under defined test conditions.
9. Reduced food-effect formulations.
10. Low-dose pediatric delivery systems.

Patent strength depends on claim breadth, prior-art density, enablement, written description, freedom-to-operate analysis, and the ability to distinguish the claimed release profile from established pseudoephedrine products. Broad claims covering conventional hypromellose matrices are likely to face substantial prior-art pressure. Narrow claims tied to unusual polymer combinations, defined coating architectures, or validated abuse-deterrent performance may be stronger commercially.

When does pseudoephedrine HCl lose exclusivity?

Pseudoephedrine HCl has no meaningful remaining composition-of-matter exclusivity in the conventional U.S. market. Immediate-release products are generally exposed to mature generic and private-label competition.

The relevant exclusivity analysis is product-specific:

Exclusivity category	Assessment
Active-ingredient patent	Generally expired or commercially irrelevant
Immediate-release formulation patents	Usually limited practical value
Extended-release formulation patents	May exist for specific branded products or delivery systems
Method-of-use patents	Limited because decongestant use is established
Regulatory exclusivity	Depends on the specific NDA, product, and approval pathway
OTC monograph pathway	Relevant for products meeting applicable FDA conditions
Biosimilar exclusivity	Not applicable
Trade-secret protection	Potentially relevant for manufacturing and coating processes

The FDA’s OTC monograph framework can reduce the value of conventional formulation patents where a product meets applicable monograph conditions. Products outside the monograph, including certain novel combinations or delivery systems, may require an NDA or other FDA pathway (FDA, 2021).

What is the Orange Book status of pseudoephedrine HCl products?

The Orange Book is not the principal competitive framework for the broad pseudoephedrine OTC market. Product-specific NDA listings, approved labeling, and patent listings must be checked separately from the general OTC monograph market.

Where a pseudoephedrine product is approved under an NDA, the relevant questions are:

• Whether the product appears in the Approved Drug Products with Therapeutic Equivalence Evaluations.
• Whether patents are listed for the specific NDA.
• Whether the listed patents cover the active ingredient, formulation, or method of use.
• Whether the product has an AB-rated generic pathway.
• Whether a Paragraph IV certification has been filed against any listed patent.

A reliable Orange Book conclusion cannot be made from the active ingredient alone. It requires the exact branded product, NDA number, dosage form, strength, and listing history.

Which companies are challenging pseudoephedrine HCl products?

The market is heavily populated by generic manufacturers, private-label suppliers, pharmacy chains, and consumer-health companies. Competition commonly includes manufacturers such as Perrigo, Teva, Kenvue, Haleon, LNK International, Major Pharmaceuticals, Rugby Laboratories, and store-brand suppliers, although participation varies by dosage form and jurisdiction.

The most relevant competitive threats are usually commercial rather than patent-litigation challenges:

• Private-label substitution.
• Retailer sourcing changes.
• Contract manufacturing bids.
• Wholesale price compression.
• Supply interruptions.
• State-level sales restrictions.
• Product withdrawal or reformulation.

Paragraph IV litigation is less central for mature immediate-release pseudoephedrine products than for newly approved extended-release or combination products. A Paragraph IV challenge would be relevant only if a listed patent remains enforceable and the generic applicant relies on an ANDA or similar abbreviated pathway.

What generic entry risks exist for pseudoephedrine HCl?

Generic entry risk is high for conventional immediate-release tablets and established liquids. A differentiated product should be evaluated against five entry vectors:

Risk	Commercial effect
Conventional ANDA or equivalent generic	Rapid price erosion after approval
Private-label substitution	Loss of shelf placement and consumer visibility
Reformulated competitor	Erosion of premium for sugar-free or dye-free claims
Combination-product competition	Diversion of consumers to multi-symptom products
Contract manufacturing replication	Fast copying of conventional excipient systems

Extended-release products may have a higher technical barrier, but the barrier is not necessarily durable. Competitors can use a different matrix, membrane, or multiparticulate architecture to design around formulation claims while matching the target release profile.

How do excipient choices create commercial opportunities?

Extended-release and once-daily products

Once-daily dosing offers the clearest consumer-facing value proposition. The technical opportunity is to achieve consistent 24-hour release without dose dumping, excessive tablet size, or pronounced food effects.

Pediatric and geriatric delivery

Liquid, chewable, mini-tablet, and orally disintegrating formats can address swallowing difficulty. Regulatory and safety constraints are important because pediatric cold-product labeling is age-sensitive, and dosing errors are a known risk in liquid medicines.

A calibrated oral syringe, unit-dose packaging, and concentration standardization can create more defensible value than taste improvement alone.

Sugar-free and low-calorie products

Sugar-free liquids can target diabetic consumers and adults who avoid sucrose. Sweetener selection must be balanced against gastrointestinal tolerance, taste persistence, and preservative performance.

Abuse-deterrent products

Pseudoephedrine is regulated as a listed chemical because it can be diverted for illicit methamphetamine production. Formulation approaches may include limiting extraction, incorporating aversive agents, binding the active in a matrix, or improving package-level controls. Any abuse-deterrent claim requires analytical and regulatory substantiation. Packaging and transaction controls may produce greater practical value than a complex excipient system alone.

Combination products

Pseudoephedrine is commonly combined with acetaminophen, ibuprofen, guaifenesin, antihistamines, or cough suppressants. Combination products can increase basket size and consumer convenience, but they create compatibility, dose-labeling, and safety risks. The formulation must account for different solubilities, pH requirements, degradation pathways, and maximum daily doses.

What manufacturing and intellectual-property barriers matter?

The main manufacturing barriers are process control and regulatory compliance rather than raw-material scarcity.

Critical controls include:

• API particle-size and flow characterization.
• Blend uniformity at low drug load.
• Lubrication control.
• Tablet hardness and friability.
• Coating weight gain and uniformity.
• Extended-release dissolution across pH conditions.
• Container-closure moisture protection.
• Preservative effectiveness for liquids.
• Tamper-evident and precursor-control packaging.
• Batch traceability and retail transaction documentation.

For extended-release products, dissolution data are often the central technical asset. A robust product should demonstrate reproducible release across batches, meaningful resistance to crushing or alcohol exposure where relevant, and an acceptable fed-state profile.

What is the regulatory status of pseudoephedrine HCl?

In the United States, pseudoephedrine sales are subject to federal precursor-control requirements. The Combat Methamphetamine Epidemic Act requires retail controls including identification verification, sales records, quantity limits, and restrictions on accessible placement. State laws may impose stricter requirements (U.S. Congress, 2005; DEA, n.d.).

FDA review depends on the product category. Conventional products may fall within applicable OTC conditions, while novel delivery systems, combinations, or products outside monograph requirements may require an NDA. Labeling must address active ingredients, dosing, contraindications, warnings, interactions, and age restrictions.

How strong is the patent estate for pseudoephedrine HCl?

The broad patent estate is weak for the active ingredient and conventional immediate-release dosage forms. The strongest potential protection is product-specific and usually relates to:

• Controlled-release architecture.
• Coating or matrix composition.
• Abuse-deterrent performance.
• Combination-product compatibility.
• Specialized pediatric delivery.
• Manufacturing methods that produce a non-obvious technical result.

A commercial diligence review should separate three categories:

1. Expired foundational patents.
2. Live patents covering a specific branded dosage form.
3. Pending applications with uncertain enforceability.

Patent strength should not be inferred from the presence of a formulation patent. Claim construction, prosecution history, terminal disclaimers, obviousness risk, and design-around options determine practical value.

What patent litigation and settlement risks affect pseudoephedrine HCl?

No broad, active patent-litigation pattern dominates the mature pseudoephedrine HCl market. Litigation risk is more likely to arise from a specific extended-release product, combination product, or abuse-deterrent platform.

A Paragraph IV dispute could delay generic entry where an NDA holder lists live formulation patents. Settlement agreements may include delayed entry, authorized generic provisions, licensing, or restrictions tied to the challenged product. These terms are product-specific and cannot be generalized across the pseudoephedrine market.

Key Takeaways

• Pseudoephedrine HCl is a mature small-molecule market with little active-ingredient patent value.
• Immediate-release tablets and conventional liquids face high generic and private-label competition.
• Extended-release formulations offer the strongest technical differentiation opportunity.
• High-solubility drug release requires careful use of hydrophilic polymers, hydrophobic matrices, or membrane coatings.
• Sugar-free, alcohol-free, dye-free, pediatric, and swallowability-focused products can support targeted commercial positioning.
• Abuse-deterrent formulation and compliant packaging have strategic value because pseudoephedrine is a regulated precursor.
• Combination products increase commercial reach but raise compatibility and labeling risks.
• Biosimilar competition is irrelevant because pseudoephedrine HCl is a small molecule.
• Orange Book and Paragraph IV analysis must be conducted at the exact product and NDA level.
• The most durable value is likely to come from integrated formulation, packaging, manufacturing, and regulatory execution rather than a broad pseudoephedrine patent position.

FAQs

Can pseudoephedrine HCl be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating format is technically feasible, but taste masking, dose loading, moisture sensitivity, and rapid drug release require careful control. The format may improve swallowing convenience but does not automatically provide a strong patent position.

Which excipient is best for 24-hour pseudoephedrine release?

No single excipient is universally optimal. High-viscosity hypromellose, ethylcellulose-based systems, acrylic polymers, and multilayer or coated multiparticulate systems can all be evaluated. The best choice depends on dose, tablet size, target dissolution profile, food effect, and manufacturing process.

Is pseudoephedrine HCl suitable for a pediatric liquid product?

It can be used in pediatric-labeled products where permitted, but age restrictions, dosing accuracy, warnings, and FDA requirements must be addressed. Unit-dose packaging and oral syringes can reduce administration errors.

Can a pseudoephedrine HCl formulation receive new patent protection?

Yes, if the formulation or manufacturing process meets novelty, non-obviousness, enablement, and other patentability requirements. Conventional excipient substitutions are less likely to support strong claims than a demonstrated release, stability, abuse-deterrence, or manufacturing improvement.

Does pseudoephedrine HCl require special commercial packaging?

In the United States, products containing pseudoephedrine are subject to precursor-control requirements. Packaging, placement, identification checks, transaction records, and quantity limits may affect the product’s retail model and operating cost.

References

1. U.S. Congress. (2005). Combat Methamphetamine Epidemic Act of 2005, Pub. L. No. 109-177, Title VII.

2. U.S. Drug Enforcement Administration. (n.d.). Retail sales of scheduled listed chemical products. U.S. Department of Justice.

3. U.S. Food and Drug Administration. (2021). Over-the-counter monograph reform. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. Rockville, MD.